Dapagliflozin Tablet, Film Coated
Product Images NDC 71335-3176

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 71335-3176). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Chemical structure of dapagliflozin depicting its molecular framework including hydroxyl groups, a chlorophenyl group, and an ethoxyphenyl substituent.*

FDA Label Image

1 (Image 2)

A scatter plot with fitted curves showing dapagliflozin dose (mg) on the x-axis versus change in 24-hour urinary glucose (g) on the y-axis. Data points distinguish observed values for healthy subjects and subjects with type 2 diabetes mellitus (T2DM) with separate fitted lines illustrating the dose-response relationship for each group.*

FDA Label Image

2 (Image 3)

A line graph depicting the HbA1c (%) adjusted mean change from baseline over 24 weeks for three treatments: Dapagliflozin 10 mg plus Metformin, Dapagliflozin 10 mg alone, and Metformin alone. The x-axis shows study weeks, and the y-axis shows percent change from baseline. A side graph displays Week 24 LOCF values with 95% confidence intervals for each treatment group.*

FDA Label Image

3 (Image 4)

A line graph depicting the adjusted mean change in HbA1c (%) from baseline over a 24-week study period comparing Dapagliflozin 10 mg + Metformin versus Placebo + Metformin. The graph shows a greater reduction in HbA1c for the Dapagliflozin + Metformin group at each time point. An additional vertical plot on the right presents HbA1c changes at week 24 with LOCF (last observation carried forward) analysis, including error bars.*

FDA Label Image

4 (Image 5)

A line graph displaying the percentage of patients with events over months from randomization, comparing Dapagliflozin and placebo groups. The x-axis represents months from 0 to 60, while the y-axis shows patients with events percentages from 0 to 7%. Two curves are shown: a solid line for Dapagliflozin and a dotted line for placebo. Below the graph, a table lists the number of patients at risk at various time points for both groups.*

FDA Label Image

5 (Image 6)

A line graph comparing the percentage of patients with an event over months from randomization between dapagliflozin and placebo. The x-axis shows time in months up to 60, and the y-axis shows patients with event percentage up to 4.5%. The graph includes patient counts at risk below the x-axis for both dapagliflozin and placebo groups at various time points.*

FDA Label Image

Label (Lbl713353176)

Dapagliflozin Tablets 10 mg film-coated oral tablets, packaged with 30 tablets per bottle. The label includes NDC 71335-3176-1 and specifies repackaging by Bryant Ranch Prepack, Inc., Burbank, CA, with manufacturing by Watson Pharma Private Ltd. Storage instructions and usage warnings are also provided on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.